STOCK TITAN

Rosalind entities (PYPD) report 9.9% PolyPid stake, with 4.56M warrant shares blocked at 9.99%

(Moderate)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Rosalind Advisors Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon report beneficial ownership in PolyPid Ltd. common shares. Based on 19,174,078 ordinary shares outstanding as of March 31, 2026, each reporting person is shown on the cover pages with 5,124,011 shares and 9.9% of the class, which reflects common shares plus shares issuable upon full warrant exercise without giving effect to ownership blockers.

The narrative ownership discussion states Rosalind Master Fund L.P. may be deemed to beneficially own 565,655 common shares, or about 2.95% of the class, excluding 4,558,356 warrant shares because a 9.99% blocker provision prevents warrant exercises that would push ownership above that threshold. Rosalind Advisors Inc. and Mr. Salamon may be deemed beneficial owners through their advisory and portfolio management roles but expressly disclaim beneficial ownership.

Positive

  • None.

Negative

  • None.
Shares outstanding 19,174,078 shares PolyPid ordinary shares outstanding as of March 31, 2026
Beneficially owned common shares 565,655 shares Shares of PolyPid common stock deemed beneficially owned by Rosalind Master Fund L.P.
Warrant shares issuable 4,558,356 shares PolyPid common shares issuable upon exercise of warrants held by Rosalind Master Fund L.P.
Total securities referenced 5,124,011 shares Common shares plus warrant shares shown on cover pages for each reporting person
Cover-page ownership percentage 9.9% Percentage of PolyPid common stock shown in Row 11 for each reporting person
Ownership excluding warrants 2.95% Approximate beneficial ownership of common stock by Rosalind Master Fund L.P., excluding warrant shares due to blocker
Ownership blocker threshold 9.99% Maximum beneficial ownership permitted before further warrant exercises are blocked
beneficial ownership financial
"may have been deemed to have the beneficial ownership of 565,655 shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
blocker provision financial
"because they contain a blocker provision under which the holder thereof does not"
warrants financial
"excludes the 4,558,356 shares issuable upon the exercise of warrants and warrant shares"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
shared dispositive power financial
"Shared Dispositive Power 5,124,011.00"
shared voting power financial
"Shared Voting Power 5,124,011.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

FAQ

What stake in PolyPid Ltd. (PYPD) is reported by Rosalind Master Fund L.P.?

Rosalind Master Fund L.P. may be deemed to beneficially own 565,655 common shares of PolyPid Ltd., representing about 2.95% of the 19,174,078 ordinary shares outstanding as of March 31, 2026.

Why does the PolyPid (PYPD) Schedule 13G/A show 9.9% ownership for Rosalind entities?

The cover pages show 5,124,011 shares, or 9.9%, including 4,558,356 shares issuable upon warrant exercise, without reflecting blockers that restrict exercises above 9.99% ownership.

How many PolyPid (PYPD) warrant shares are referenced for Rosalind Master Fund L.P.?

The filing references 4,558,356 shares of PolyPid common stock that are issuable upon exercise of warrants, but these are subject to a 9.99% blocker provision limiting exercisability.

What is the blocker provision affecting Rosalind’s PolyPid (PYPD) warrants?

The warrants contain a 9.99% blocker provision, under which the holder cannot exercise any portion of the warrants if doing so would result in beneficial ownership exceeding 9.99% of PolyPid’s common stock.

Do Rosalind Advisors Inc. and Steven Salamon claim full beneficial ownership of PolyPid (PYPD) shares?

Rosalind Advisors Inc. and Steven Salamon may be deemed to beneficially own shares held by Rosalind Master Fund L.P., but they expressly disclaim beneficial ownership of those PolyPid shares.

What PolyPid (PYPD) share count is used to calculate the reported ownership percentages?

Ownership percentages are calculated using 19,174,078 ordinary shares of PolyPid common stock outstanding as of March 31, 2026, as disclosed in a Form 6-K issued on May 13, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





M8001Q126

(CUSIP Number)
07/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: This percentage is calculated based upon 19,174,078 Ordinary shares of the Issuers common stock outstanding as of March 31, 2026, based on the 6K issued by Polypid Ltd on May 13, 2026. However, as more fully described in Item 4, the securities reported in rows 6, 8 and 9 show the number of shares of Common Stock that would be issuable upon full conversion and exercise of such reported securities and do not give effect to such blockers. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows 6, 8 and 9. (6) 565,655 shares of Common Stock 4,558,356 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 565,655 shares of Common Stock 4,558,356 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 565,655 shares of Common Stock 4,558,356 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6) 565,655 shares of Common Stock 4,558,356 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Rosalind Advisors, Inc.
Signature:Steven Salamon
Name/Title:President
Date:08/12/2026
SALAMON STEVEN A J
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:08/12/2026
Aharon Gil
Signature:Gil Aharon
Name/Title:Gil Aharon
Date:08/12/2026
Rosalind Master Fund L.P.
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:08/12/2026